Similar articles

Abstract: Epidemiological evidence suggests that patients with hypertension infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are at increased risk of acute lung injury. However, it is still not clear whether this increased risk is related to the usage of renin-angiotensin system (RAS) blockers. We collected medical records of coronavirus disease 2019 (COVID-19) patients from the First Affiliated Hospital, Zhejiang University School of Medicine (Hangzhou, China), and evaluated the potential impact of an angiotensin II receptor blocker (ARB) on the clinical outcomes of COVID-19 patients with hypertension. A total of 30 hypertensive COVID-19 patients were enrolled, of which 17 were classified as non-ARB group and the remaining 13 as ARB group based on the antihypertensive therapies they received. Compared with the non-ARB group, patients in the ARB group had a lower proportion of severe cases and intensive care unit (ICU) admission as well as shortened length of hospital stay, and manifested favorable results in most of the laboratory testing. Viral loads in the ARB group were lower than those in the non-ARB group throughout the disease course. No significant difference in the time of seroconversion or antibody levels was observed between the two groups. The median levels of soluble angiotensin-converting enzyme 2 (sACE2) in serum and urine samples were similar in both groups, and there were no significant correlations between serum sACE2 and biomarkers of disease severity. Transcriptional analysis showed 125 differentially expressed genes which mainly were enriched in oxygen transport, bicarbonate transport, and blood coagulation. Our results suggest that ARB usage is not associated with aggravation of COVID-19. These findings support the maintenance of ARB treatment in hypertensive patients diagnosed with COVID-19.

血管紧张素受体阻滞剂使用对COVID-19高血压患者病毒载量、抗体水平和转录特征的影响

[1]BeanDM, KraljevicZ, SearleT, et al., 2020. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust. Eur J Heart Fail, 22(6):967-974.

[2]CoxRJ, BrokstadKA, 2020. Not just antibodies: B cells and T cells mediate immunity to COVID-19. Nat Rev Immunol, 20(10):581-582.

[3]FangL, KarakiulakisG, RothM, 2020. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med, 8(4):e21.

[4]FosbolEL, ButtJH, ØstergaardL, et al., 2020. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA, 324(2):168-177.

[5]GaoC, CaiY, ZhangK, et al., 2020. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J, 41(22):2058-2066.

[6]GrasselliG, GrecoM, ZanellaA, et al., 2020. Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy. JAMA Intern Med, 180(10):1345-1355.

[7]ImaiY, KubaK, RaoS, et al., 2005. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature, 436(7047):112-116.

[8]KreutzR, EAEHAlgharably, AziziM, et al., 2020. Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19: European Society of Hypertension COVID-19 Task Force Review of Evidence. Cardiovasc Res, 116(10):1688-1699.

[9]KubaK, ImaiY, RaoS, et al., 2005. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med, 11(8):875-879.

[10]LamKW, ChowKW, VoJ, et al., 2020. Continued in-hospital angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use in hypertensive COVID-19 patients is associated with positive clinical outcome. J Infect Dis, 222(8):1256-1264.

[11]LanJ, GeJW, YuJF, et al., 2020. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature, 581(7807):215-220.

[12]LeviM, ThachilJ, IbaT, et al., 2020. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol, 7(6):e438-e440.

[13]LiaoDY, ZhouF, LuoLL, et al., 2020. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol, 7(9):e671-e678.

[14]LiuX, SperanzaE, Munoz-FontelaC, et al., 2017. Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus. Genome Biol, 18:4.

[15]MackeyK, KingVJ, GurleyS, et al., 2020. Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults: a living systematic review. Ann Intern Med, 173(3):195-203.

[16]ManciaG, ReaF, LudergnaniM, et al., 2020. Renin-angiotensin-aldosterone system blockers and the risk of COVID-19. New Engl J Med, 382(25):2431-2440.

[17]MehtaN, KalraA, NowackiAS, et al., 2020. Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol, 5(9):1020-1026.

[18]MengJ, XiaoGH, ZhangJJ, et al., 2020. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect, 9(1):757-760.

[19]National Health Commission of the People’s Republic of China, 2020. Guideline for diagnosis and treatment of SARS-CoV-2 (the 7th edition). http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml(in Chinese).

[20]PintoBGG, OliveiraAER, SinghY, et al., 2020. ACE2 expression is increased in the lungs of patients with comorbidities associated with severe COVID-19. J Infect Dis, 222(4):556-563.

[21]RomagnoliS, PerisA, de GaudioAR, et al., 2020. SARS-CoV-2 and COVID-19: from the bench to the bedside. Physiol Rev, 100(4):1455-1466.

[22]ShangJ, YeG, ShiK, et al., 2020. Structural basis of receptor recognition by SARS-CoV-2. Nature, 581(7807):221-224.

[23]VistisenST, BodilsenJ, ScheerenTWL, et al., 2020. Risk and prognosis of COVID-19 in patients treated with renin-angiotensin-aldosterone inhibitors. Eur J Anaesthesiol, 37(9):739-742.

[24]World Health Organization, 2020. Coronavirus disease (COVID-19): weekly epidemiological update and weekly operational update. Technical Report. World Health Organization, Geneva. https://www.who.int/publications/m/item/weekly-epidemiological-update---16-march-2021

[25]WrappD, WangNS, CorbettKS, et al., 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science, 367(6483):1260-1263.

[26]YangG, TanZH, ZhouL, et al., 2020. Effects of angiotensin II receptor blockers and ACE (angiotensin-converting enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: a single-center retrospective study. Hypertension, 76(1):51-58.

[27]ZhangJS, WangML, DingW, et al., 2020. The interaction of RAAS inhibitors with COVID-19: current progress, perspective and future. Life Sci, 257:118142.

[28]ZhangP, ZhuLH, CaiJJ, et al., 2020. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res, 126(12):1671-1681.

[29]ZhengSF, FanJ, YuF, et al., 2020. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang Province, China, January‒March 2020: retrospective cohort study. BMJ, 369:m1443.

[30]ZhengYY, MaYT, ZhangJY, et al., 2020. COVID-19 and the cardiovascular system. Nat Rev Cardiol, 17(5):259-260.